<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><atom:link href="https://www.dovepress.com/feed/journal/136" rel="self" type="application/rss+xml"/><title>Orphan Drugs: Research and Reviews</title><link>https://www.dovepress.com/feed/journal/136</link><description>New articles released by Dove Press for Orphan Drugs: Research and Reviews</description><language>en-us</language><copyright>2026, Dove Press</copyright><webMaster>angela@dovepress.com (Angela Jones)</webMaster><generator>Dove Press Orphan Drugs: Research and Reviews</generator><image><title>Orphan Drugs: Research and Reviews</title><link>https://www.dovepress.com/feed/journal/136</link><url>https://www.dovepress.com/assets/img/addon/rss-banner.jpg</url><width>140</width><height>140</height></image><item><title>Orphan drugs for the treatment of aspergillosis: focus on isavuconazole</title><link>https://www.dovepress.com/orphan-drugs-for-the-treatment-of-aspergillosis-focus-on-isavuconazole-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Wed, 03 May 2017 11:40:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S126518</guid></item><item><title>Spotlight on anagrelide hydrochloride for the treatment of essential thrombocythemia</title><link>https://www.dovepress.com/spotlight-on-anagrelide-hydrochloride-for-the-treatment-of-essential-t-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Tue, 31 Jan 2017 15:53:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S93451</guid></item><item><title>Nitisinone: a review</title><link>https://www.dovepress.com/nitisinone-a-review-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Tue, 31 Jan 2017 15:23:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S92995</guid></item><item><title>Pompe disease: clinical perspectives</title><link>https://www.dovepress.com/pompe-disease-clinical-perspectives-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Wed, 28 Dec 2016 14:41:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S69109</guid></item><item><title>Adverse events reported for hereditary angioedema medications: a retrospective study of spontaneous reports submitted to the EudraVigilance database, 2007-2013</title><link>https://www.dovepress.com/adverse-events-reported-for-hereditary-angioedema-medications-a-retros-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Tue, 03 May 2016 13:41:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S94790</guid></item><item><title>Denosumab in the treatment of hypercalcemia secondary to malignancy</title><link>https://www.dovepress.com/denosumab-in-the-treatment-of-hypercalcemia-secondary-to-malignancy-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Mon, 23 Nov 2015 11:53:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S78991</guid></item><item><title>Orphan drugs for sickle vaso-occlusion: dawn of a new era of targeted treatment</title><link>https://www.dovepress.com/orphan-drugs-for-sickle-vaso-occlusion-dawn-of-a-new-era-of-targeted-t-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Mon, 02 Nov 2015 12:14:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S46305</guid></item><item><title>Orphan drugs in development for primary biliary cirrhosis: challenges and progress</title><link>https://www.dovepress.com/orphan-drugs-in-development-for-primary-biliary-cirrhosis-challenges-a-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Thu, 10 Sep 2015 13:52:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S69477</guid></item><item><title>Paroxysmal nocturnal hemoglobinuria: new concepts in pathophysiology and treatment</title><link>https://www.dovepress.com/paroxysmal-nocturnal-hemoglobinuria-new-concepts-in-pathophysiology-an-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Tue, 01 Sep 2015 15:04:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S73641</guid></item><item><title>The efficacy and safety of adalimumab in ocular inflammatory disease</title><link>https://www.dovepress.com/the-efficacy-and-safety-of-adalimumab-in-ocular-inflammatory-disease-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Mon, 31 Aug 2015 11:55:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S69582</guid></item><item><title>Profile of lumacaftor/ivacaftor combination: potential in the treatment of cystic fibrosis</title><link>https://www.dovepress.com/profile-of-lumacaftorivacaftor-combination-potential-in-the-treatment--peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Fri, 14 Aug 2015 11:51:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S78413</guid></item><item><title>Drugs in development and dietary approach for Duchenne muscular dystrophy</title><link>https://www.dovepress.com/drugs-in-development-and-dietary-approach-for-duchenne-muscular-dystro-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Tue, 11 Aug 2015 15:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S55677</guid></item><item><title>Fahr's disease: current perspectives</title><link>https://www.dovepress.com/fahr39s-disease-current-perspectives-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Thu, 16 Jul 2015 17:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S63388</guid></item><item><title>Orphan drugs in development for long-chain fatty acid oxidation disorders: challenges and progress</title><link>https://www.dovepress.com/orphan-drugs-in-development-for-long-chain-fatty-acid-oxidation-disord-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Tue, 28 Apr 2015 11:55:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S63061</guid></item><item><title>Amyotrophic lateral sclerosis: clinical perspectives</title><link>https://www.dovepress.com/amyotrophic-lateral-sclerosis-clinical-perspectives-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Wed, 15 Apr 2015 10:52:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S63585</guid></item><item><title>Update on the challenges of treating trigeminal neuralgia</title><link>https://www.dovepress.com/update-on-the-challenges-of-treating-trigeminal-neuralgia-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Fri, 10 Apr 2015 10:49:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S53046</guid></item><item><title>Orphan drugs in development for Huntington's disease: challenges and progress</title><link>https://www.dovepress.com/orphan-drugs-in-development-for-huntington39s-disease-challenges-and-p-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Thu, 12 Feb 2015 13:37:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S49198</guid></item><item><title>Optimal management of interstitial lung disease associated with dermatomyositis/polymyositis: lessons from the Japanese experience</title><link>https://www.dovepress.com/optimal-management-of-interstitial-lung-disease-associated-with-dermat-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Fri, 21 Nov 2014 11:44:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S50355</guid></item><item><title>Orphan drugs in glioblastoma multiforme: a review</title><link>https://www.dovepress.com/orphan-drugs-in-glioblastoma-multiforme-a-review-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Fri, 14 Nov 2014 14:53:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S46018</guid></item><item><title>New treatments in development for Pseudomonas aeruginosa infections in the lungs of individuals with cystic fibrosis</title><link>https://www.dovepress.com/new-treatments-in-development-for-pseudomonas-aeruginosa-infections-in-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Fri, 24 Oct 2014 15:41:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S50014</guid></item><item><title>Orphan drugs in development for urea cycle disorders: current perspectives</title><link>https://www.dovepress.com/orphan-drugs-in-development-for-urea-cycle-disorders-current-perspecti-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Tue, 30 Sep 2014 14:27:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S44065</guid></item><item><title>Angiogenesis inhibitors in gastric cancer</title><link>https://www.dovepress.com/angiogenesis-inhibitors-in-gastric-cancer-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Mon, 14 Jul 2014 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S36731</guid></item><item><title>An update on gene therapy for the treatment of lipoprotein lipase deficiency</title><link>https://www.dovepress.com/an-update-on-gene-therapy-for-the-treatment-of-lipoprotein-lipase-defi-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Thu, 15 May 2014 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S39979</guid></item><item><title>Access to cross-border health care services for patients with rare diseases in the European Union</title><link>https://www.dovepress.com/access-to-cross-border-health-care-services-for-patients-with-rare-dis-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Fri, 11 Apr 2014 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S58268</guid></item><item><title>Stiripentol for the treatment of Dravet syndrome</title><link>https://www.dovepress.com/stiripentol-for-the-treatment-of-dravet-syndrome-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Wed, 02 Apr 2014 00:00:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S47619</guid></item><item><title>A 30-year retrospective: National Organization for Rare Disorders, the Orphan Drug Act, and the role of rare disease patient advocacy groups</title><link>https://www.dovepress.com/a-30-year-retrospective-national-organization-for-rare-disorders-the-o-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Mon, 17 Feb 2014 00:00:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S41070</guid></item><item><title>Profile of aminopyridines for Lambert–Eaton myasthenic syndrome</title><link>https://www.dovepress.com/profile-of-aminopyridines-for-lambertndasheaton-myasthenic-syndrome-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Mon, 20 Jan 2014 00:00:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S40799</guid></item><item><title>Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations</title><link>https://www.dovepress.com/post-marketing-access-to-orphan-drugs-a-critical-analysis-of-health-te-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Thu, 09 Jan 2014 00:00:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S43409</guid></item><item><title>Do ultra-orphan medicinal products warrant ultra-high prices? A review</title><link>https://www.dovepress.com/do-ultra-orphan-medicinal-products-warrant-ultra-high-prices-a-review-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Mon, 24 Jun 2013 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S33085</guid></item><item><title>Tipifarnib and farnesyltransferase inhibitors in the treatment of inflammatory breast cancer: is the story over? A review</title><link>https://www.dovepress.com/tipifarnib-and-farnesyltransferase-inhibitors-in-the-treatment-of-infl-peer-reviewed-fulltext-article-ODRR</link><category>Orphan Drugs: Research and Reviews</category><pubDate>Wed, 15 May 2013 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/ODRR.S35339</guid></item></channel></rss>
